News >

Future of Molecular Testing in NSCLC Lies in Larger DNA and RNA Analysis

Kristi Rosa
Published: Wednesday, Nov 20, 2019

Jeremy Segal, MD, PhD, director of Genomic and Molecular Pathology Unit and associate professor of pathology, Department of Pathology, University of Chicago

Jeremy Segal, MD, PhD

The future of molecular testing in non–small cell lung cancer (NSCLC) lies in combined large-scale DNA and RNA analysis, said Jeremy Segal, MD, PhD, adding that expanded sequencing can increase the detection of targetable mutations or molecular signatures and can also help avoid misdiagnosis.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication